GPC Biotech Merger into new Agennix AG on track to close before the end of 2009

12-Oct-2009 - GPC Biotech AG reported that its planned merger, under which the Company will combine its business with Agennix Incorporated remains on track to close before the end of 2009. The Company resulting from the merger will be called Agennix AG. The Company also reported a change to the future ...

GPC Biotech Shareholders Approve Merger into New Agennix AG

24-Jun-2009 - GPC Biotech AG announced that the shareholders' meeting approved the adoption of the merger agreement between the Company and diagennix GmbH (to be renamed Agennix AG and converted into a stock corporation). Pursuant to the merger agreement, GPC Biotech, as transferring entity, is to be merged ...

GPC Biotech and Agennix Announce Proposed Merger

Pipeline to include novel oncology therapy, talactoferrin, which recently entered Phase 3 clinical testing

20-Feb-2009 - GPC Biotech AG and Agennix, Incorporated announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses. In the transaction, GPC Biotech is to be merged onto a new German company, which will hold ...

GPC Biotech Reports that Marketing Authorization Application for Satraplatin is to be Withdrawn

29-Jul-2008 - GPC Biotech AG reported that the Company has been informed by its partner for satraplatin in Europe that they plan to withdraw the Marketing Authorization Application (MAA) for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy ...

GPC Biotech Announces Granting of European Patent Related to Satraplatin for Treating Tumors Resistant or Refractory to Taxanes

17-Jun-2008 - GPC Biotech AG announced the granting of a European Patent (EP 1 720 540 B1) related to satraplatin, an oral platinum compound. The patent is entitled, "Satraplatin for treating resistant or refractory tumors" and covers certain uses of satraplatin related to the treatment of a cancer or tumor ...

GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer

05-Dec-2007 - GPC Biotech AG announced the appointment of Torsten Hombeck, Ph.D., to Chief Financial Officer. Dr. Hombeck will assume his duties on January 1, 2008. Dr. Hombeck will replace Mirko Scherer, Ph.D., who is resigning from the Company, effective immediately, to pursue other interests. Dr. Scherer ...

GPC Biotech Withdraws Satraplatin NDA Filed for Accelerated Approval

Company Plans to Resubmit Application Pending Final Survival Analysis

01-Aug-2007 - GPC Biotech AG announced that it has withdrawn the satraplatin capsules New Drug Application (NDA) filed for accelerated approval for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed. The Company based its decision on the vote by the Oncologic Drugs ...

GPC Biotech AG Named in Purported Class Action Lawsuit in the United States

31-Jul-2007 - GPC Biotech AG announced that it has been sued in the United States District Court for the Southern District of New York, purportedly in a class action lawsuit on behalf of all persons who purchased or acquired securities of GPC Biotech between December 5, 2005 and July 24, 2007 inclusive. Bernd ...

GPC Biotech Consolidates Drug Discovery Activities

Waltham, Massachusetts Facility to be Closed

08-May-2007 - GPC Biotech AG announced that it is consolidating its drug discovery efforts to one location. This consolidation involves closing the Company's facility in Waltham, Massachusetts and a staff reduction involving approximately 16% of the Company's total workforce. Affected employees will be ...

FDA Accepts GPC Biotech's Satraplatin NDA for Filing and Grants Priority Review Status

17-Apr-2007 - GPC Biotech AG announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. The Company ...